stockrow
Friday 6 November 2026
Export AKBA’s income statement to Excel — free account
Akebia Therapeutics, Inc.
AKBA Healthcare Drug Manufacturers Specialty & Generic
Akebia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $236.2 million, up 47.5% from fiscal 2024.
- Revenue
- −37.2%
- EPS
- −2,600.0%
- Free cash flow
- −94.2%
- Total debt
- +5.52%
Quarter to September 2026, against a year earlier
0.41
0.02
−4.65%
Follow AKBA
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.29 | 1.40 | 1.60 | 1.75 | |
P/FCF ratio |
18.38 | 7.63 | 6.18 | 6.10 | |
P/Operating CF |
109.23 | 87.19 | (17.50) | 13.30 | |
P/B ratio |
12.51 | 12.29 | 13.56 | 12.70 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.74 | 0.92 | 1.11 | 1.25 | |
EV/EBITDA |
0.00 | 0.00 | 39.17 | 11.91 | |
EV/Operating CF |
9.24 | 4.85 | 4.26 | 4.34 | |
EV/FCF |
10.51 | 5.00 | 4.29 | 4.35 | |
Quick Ratio |
1.21 | 1.30 | 1.30 | 1.42 | |
Current Ratio |
1.36 | 1.43 | 1.40 | 1.55 | |
Net Debt/EBITDA |
0.00 | 18.46 | 26.04 | 16.59 | |
Debt/Assets |
14.69% | 14.17% | 13.49% | 12.81% | |
Debt/Equity |
2.47 | 1.98 | 1.79 | 1.48 | |
Asset Turnover |
0.56 | 0.63 | 0.69 | 0.79 | |
Operating CF/Net income |
(0.16) | (0.40) | 2.34 | (2.54) | |
Capex/Depreciation |
0.00 | (1.84) | (0.19) | (0.22) | |
Interest Coverage |
(3.65) | (2.06) | (1.00) | (1.77) | |
Research and Development Expense of Revenue |
43.85% | 28.62% | 27.65% | 46.25% | |
Selling, General and Administrative Expense of Revenue |
63.76% | 57.34% | 56.84% | 45.28% | |
Intangible Assets out of Total Assets |
0.17 | 0.17 | 0.16 | 0.16 | |
Share Based Compensation of Revenue |
7.59% | 6.57% | 6.85% | 5.55% | |
Graham Net Nets |
(0.40) | (0.31) | (0.25) | (0.22) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(17.39%) | (9.47%) | (5.55%) | (1.06%) | |
Free Cash Flow Yield |
5.44% | 13.10% | 16.17% | 16.39% | |
Revenue per Share |
0.13 | 0.18 | 0.20 | 0.22 | |
Operating CF per Share |
0.01 | 0.01 | (0.08) | 0.12 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.01 | 0.01 | (0.08) | 0.12 | |
Cash per Share |
0.58 | 0.58 | 0.61 | 0.72 | |
Shareholders Equity per Share |
0.07 | 0.09 | 0.10 | 0.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.07 | 0.09 | 0.10 | 0.13 | |
Free Cash Flow |
1.63 | 2.45 | (21.27) | 31.06 | |
Working Capital |
58.44 | 68.69 | 69.60 | 90.02 | |
Capital Expenditures |
(0.71) | (1.08) | (0.06) | (0.07) | |
Net Current Asset Value |
(100.97) | (95.09) | (91.66) | (91.00) | |
EV/EBIT |
0.00 | 0.00 | 48.67 | 12.55 | |
Capex to Sales |
0.02 | 0.02 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 70.18 | 17.62 | |
| Other line items | |||||
Average Receivables |
51.33 | 63.16 | 62.04 | 40.70 | |
Average Payables |
8.85 | 10.49 | 10.52 | 18.18 | |
Average Inventory |
18.67 | 14.86 | 16.36 | 15.93 | |
Average Assets |
353.14 | 347.63 | 336.35 | 298.62 | |
Average Common Equity |
30.98 | 27.12 | 25.98 | (8.29) |
Columns are period end dates · fundamentals updated 5 Nov 2026